Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective

被引：9

作者：

Aapro, Matti ^{[1
]}

Zhang, Li ^{[2
]}

Yennu, Sriram ^{[3
]}

LeBlanc, Thomas W. ^{[4
]}

Schwartzberg, Lee ^{[5
]}

机构：

[1] Genolier Canc Ctr, Clin Genolier, Genolier, Switzerland

[2] Sun Yat Sen Univ, State Key Lab Oncol South China, Dept Med Oncol, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Guangdong, Peoples R China

[3] Univ Texas MD Anderson Canc Ctr, Dept Palliat Rehabil & Integrat Med, Div Canc Med, Houston, TX 77030 USA

[4] Duke Univ, Sch Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27705 USA

[5] West Clin, Dept Hematol & Oncol, Germantown, TN 38138 USA

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 10期

关键词：

antiemetics; CINV; nausea; NEPA; netupitant; palonosetron; vomiting; HIGHLY EMETOGENIC CHEMOTHERAPY; RANDOMIZED PHASE-III; PLACEBO-CONTROLLED TRIAL; NK1 RECEPTOR ANTAGONIST; P-MEDIATED RESPONSES; HIGH-DOSE CISPLATIN; DOUBLE-BLIND; NEUROKININ-1; RECEPTOR; 5-HYDROXYTRYPTAMINE-RECEPTOR ANTAGONISTS; ORAL COMBINATION;

D O I：

10.2217/fon-2018-0872

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients receiving appropriate antiemetic treatment. However, inadequate uptake of current antiemetic guideline recommendations by physicians, and poor treatment adherence by patients, lead to suboptimal CINV control. There is an unmet need to optimize guideline-consistent use of antiemetics to improve CINV management and prevention.Herein, we provide an overview of CINV, then discuss oral and intravenous NEPA, the first fixed combination antiemetic, composed of netupitant/fosnetupitant and palonosetron. We describe the main pharmacologic and pharmacokinetic characteristics of NEPA, and review the clinical evidence supporting its use in the prevention of CINV.

引用

页码：1067 / 1084

页数：18

共 104 条

[31] Evaluation of the Effect of Food and Age on the Pharmacokinetics of Oral Netupitant and Palonosetron in Healthy Subjects: A Randomized, Open-Label, Crossover Phase 1 Study [J].

Calcagnile, Selma ;

Lanzarotti, Corinna ;

Gutacker, Michaela ;

Jakob-Rodamer, Verena ;

Kammerer, Klaus Peter ;

Timmer, Wolfgang .

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (05) :377-386

[32] Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives [J].

Calcagnile, Selma ;

Lanzarotti, Corinna ;

Rossi, Giorgia ;

Henriksson, Anders ;

Kammerer, Klaus Peter ;

Timmer, Wolfgang .

SUPPORTIVE CARE IN CANCER, 2013, 21 (10) :2879-2887

[33] Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis [J].

Chow, Ronald ;

Warr, David G. ;

Navari, Rudolph M. ;

Tsao, May ;

Popovic, Marko ;

Chiu, Leonard ;

Milakovic, Milica ;

Lam, Henry ;

DeAngelis, Carlo .

SUPPORTIVE CARE IN CANCER, 2018, 26 (08) :2519-2549

[34] Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses [J].

Clark-Snow, Rebecca ;

Affronti, Mary Lou ;

Rittenberg, Cynthia N. .

SUPPORTIVE CARE IN CANCER, 2018, 26 (02) :557-564

[35]

Dibble S.L., 2003, Oncology nursing forum, V30, P40

[36] Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey [J].

Dielenseger, Pascale ;

Borjeson, Sussanne ;

Vidall, Cheryl ;

Young, Annie ;

Jahn, Patrick .

SUPPORTIVE CARE IN CANCER, 2019, 27 (11) :4099-4106

[37] The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting [J].

Dranitsaris, G. ;

Molassiotis, A. ;

Clemons, M. ;

Roeland, E. ;

Schwartzberg, L. ;

Dielenseger, P. ;

Jordan, K. ;

Young, A. ;

Aapro, M. .

ANNALS OF ONCOLOGY, 2017, 28 (06) :1260-1267

[38] Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study [J].

Eisenberg, P ;

MacKintosh, FR ;

Ritch, P ;

Cornett, PA ;

Macciocchi, A .

ANNALS OF ONCOLOGY, 2004, 15 (02) :330-337

[39] An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting [J].

Fabi, Alessandra ;

Malaguti, Paola .

EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (05) :629-641

[40]

Gilbar Peter, 2009, J Oncol Pharm Pract, V15, P233, DOI 10.1177/1078155209102336

← 1 2 3 4 5 6 7 8 9 10 →